Compounds and Compositions for the Treatment of Parasitic Diseases (2014)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,303,034 | Compounds and Compositions for the Treatment of Parasitic Diseases In force · High confidence UsedRemaining | Irm LLC | In force | High confidence | ||
| US 9,700,559 | Compounds and Compositions for the Treatment of Parasitic Diseases In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,085,989 | Compounds and Compositions for the Treatment of Parasitic Diseases In force · High confidence | Novartis Internatonal Pharmaceutical AG | In force | High confidence | ||
| US 10,596,175 | Compounds and Compositions for the Treatment of Parasitic Diseases In force · High confidence | Novartis AG | In force | High confidence | ||
| Application 17/398,852 | Compounds and Compositions for the Treatment of Parasitic Diseases Abandoned Abandoned Nov 30, 2023 | Novartis AG | Abandoned | Abandoned Nov 30, 2023 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Irm LLC.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.